Tomera, K <br/><br/>
The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.  [electronic resource] 

 -  The Journal of urology  May 2001 
 - 1585-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0022-5347 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Androgen Antagonists--therapeutic use<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Delayed-Action Preparations<br/>Dihydrotestosterone--blood<br/>Follicle Stimulating Hormone--blood<br/>Gonadotropin-Releasing Hormone--agonists<br/>Goserelin--therapeutic use<br/>Humans<br/>Injections, Intramuscular<br/>Leuprolide--therapeutic use<br/>Luteinizing Hormone--blood<br/>Male<br/>Middle Aged<br/>Oligopeptides--administration & dosage<br/>Prospective Studies<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood<br/>Testis--drug effects<br/>Testosterone--blood